Table 2B:
Breast cancer-specific survival in relation
to OC use, stratified by age at diagnosis.
|
|
n |
HR crude (95% CI) |
d/m |
HR adjustedc
(95% CI) |
d/m |
HR adjustedd
(95% CI) |
d/m |
|
40-55 |
116 |
|
18/0 |
|
18/1 |
|
16/48 |
|
OC never |
30 |
1.00 |
6/0 |
1.00 |
6/0 |
1.00 |
6/15 |
|
OC ever |
86 |
0.69 (0.26-1.84) |
12/0 |
0.77 (0.28-2.11) |
12/1 |
0.80 (0.20-3.03) |
10/33 |
|
56-70 |
471 |
|
60/1 |
|
59/6 |
|
35/223 |
|
OC never |
204 |
1.00 |
28/0 |
1.00 |
28/1 |
1.00 |
19/96 |
|
OC ever |
267 |
0.98 (0.59-1.63) |
32/1 |
0.94 (0.56-1.57) |
31/5 |
0.83 (0.41-1.70) |
16/127 |
|
71- |
177 |
|
37/0 |
|
36/3 |
|
19/80 |
|
OC never |
130 |
1.00 |
33/0 |
1.00 |
32/3 |
1.00 |
18/59 |
|
OC ever |
47 |
0.33 (0.12-0.93)* |
4/0 |
0.35 (0.12-1.01) |
4/0 |
0.17 (0.02-1.40) |
1/21 |
N(number) stands for total
cases included in the analysis, d for total deaths and m for missing data.
cAdjusted
for BMI, and socioeconomic status
d Adjusted
for BMI, socioeconomic status, size of tumor, lymphnod einvolvement, grade of tumor
(according to Nottingham), PgR, ER, HER2, P27, Ki67.
*Significance.
Confidence interval separate from 1.00.